Zealand Pharma Announces Topline Results From 13-Week Phase 1b Multiple Ascending Dose Clinical Trial With GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide; Placebo-Adjusted Reductions In Body Weight Of Up To A Mean Of 8.3% With Dapiglutide After 13 Weekly Doses

Author: Benzinga Newsdesk | September 09, 2024 11:04am

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

• Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses
• Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies
• Higher doses up to 26 mg over a 28-week treatment period are being evaluated in the ongoing Part 2 of the trial with topline results expected in the first half of 2025

Copenhagen, Denmark, 9 September 2024 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces positive topline clinical results from a Phase 1b multiple ascending dose (MAD) trial, investigating safety, tolerability, and clinical effects of 13 weeks of dosing with dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist in development for weight management1.

Posted In: ZEAL